Equities analysts predict that Champions Oncology Inc (NASDAQ:CSBR) will announce earnings per share of $0.03 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Champions Oncology’s earnings, with the highest EPS estimate coming in at $0.03 and the lowest estimate coming in at $0.02. The business is expected to announce its next earnings results on Thursday, March 21st.
According to Zacks, analysts expect that Champions Oncology will report full year earnings of $0.12 per share for the current fiscal year, with EPS estimates ranging from $0.10 to $0.14. For the next financial year, analysts anticipate that the company will post earnings of $0.25 per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings results on Monday, December 17th. The biotechnology company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $6.69 million during the quarter, compared to the consensus estimate of $6.35 million. Champions Oncology had a net margin of 0.05% and a return on equity of 1.44%.
Separately, Zacks Investment Research cut shares of Champions Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 14th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $11.33.
CSBR stock traded down $0.07 during trading on Monday, reaching $10.93. The company had a trading volume of 23,263 shares, compared to its average volume of 59,224. The stock has a market capitalization of $125.48 million, a PE ratio of -78.07 and a beta of 1.63. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.05. Champions Oncology has a twelve month low of $3.25 and a twelve month high of $17.90.
In related news, CEO Ronnie Morris bought 20,000 shares of the stock in a transaction that occurred on Wednesday, December 19th. The stock was bought at an average cost of $7.44 per share, for a total transaction of $148,800.00. Following the purchase, the chief executive officer now directly owns 833,001 shares of the company’s stock, valued at $6,197,527.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 44.30% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Champions Oncology by 1.2% in the fourth quarter. BlackRock Inc. now owns 125,011 shares of the biotechnology company’s stock worth $976,000 after acquiring an additional 1,471 shares in the last quarter. Sandy Spring Bank purchased a new position in Champions Oncology in the fourth quarter worth $205,000. Acadian Asset Management LLC raised its position in Champions Oncology by 49.9% in the fourth quarter. Acadian Asset Management LLC now owns 107,173 shares of the biotechnology company’s stock worth $836,000 after acquiring an additional 35,689 shares in the last quarter. ClariVest Asset Management LLC raised its position in Champions Oncology by 29.6% in the fourth quarter. ClariVest Asset Management LLC now owns 39,800 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 9,100 shares in the last quarter. Finally, Vanguard Group Inc raised its position in Champions Oncology by 51.4% in the third quarter. Vanguard Group Inc now owns 231,150 shares of the biotechnology company’s stock worth $4,038,000 after acquiring an additional 78,428 shares in the last quarter. Institutional investors own 49.48% of the company’s stock.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.